Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å evaluere effektiviteten av to doser AP-472 som tilleggsterapi til levodopa hos deltakere med Parkinsons sykdom (PD) med motoriske fluktuasjoner

26. oktober 2026 oppdatert av: Appello Pharmaceuticals, Inc.

Fase 2, dobbeltblind, placebokontrollert studie for å evaluere effektiviteten av to doser av AP-472 som tilføyelsesterapi til levodopa hos deltakere med Parkinsons sykdom (PD) med motoriske fluktuasjoner

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.

The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given.

The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

150

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205-5551
        • Rekruttering
        • University of Arkansas for Medical Sciences (Site #208)
    • California
      • Carlsbad, California, Forente stater, 92011
        • Rekruttering
        • Profound Research LLC (Site #222)
      • Los Alamitos, California, Forente stater, 90720-3108
        • Rekruttering
        • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS (Site #217)
      • Los Angeles, California, Forente stater, 90033-5310
        • Rekruttering
        • Keck Medicine of USC - USC Healthcare Center 2 (Site #221)
      • Palo Alto, California, Forente stater, 94301
        • Rekruttering
        • Parkinson's Research Centers of America (Site #218)
    • Colorado
      • Englewood, Colorado, Forente stater, 80113-2776
        • Rekruttering
        • Rocky Mountain Clinical Research - CenExel - PPDS (Site #215)
    • Florida
      • Boca Raton, Florida, Forente stater, 33486
        • Rekruttering
        • Parkinson's Disease & Movement Disorders Center of Boca Raton (Site #227)
      • Boca Raton, Florida, Forente stater, 33486
        • Rekruttering
        • UM-UHealth at Boca Raton (Site #226)
      • Hallandale, Florida, Forente stater, 33009
        • Rekruttering
        • Velocity Clinical Research - Hallandale Beach (Site #228)
      • Miami, Florida, Forente stater, 33136-1051
        • Rekruttering
        • University of Miami (Site #220)
      • Orlando, Florida, Forente stater, 32825
        • Rekruttering
        • Neurology One (Site #205)
      • Tampa, Florida, Forente stater, 33613-4808
        • Rekruttering
        • USF Parkinson's Disease and Movement Disorders Center (Site #206)
    • Georgia
      • Augusta, Georgia, Forente stater, 30912-0020
        • Rekruttering
        • Augusta University Medical Center (Site #212)
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46256
        • Rekruttering
        • Josephson Wallack Munshower Neurology PC (Site #231)
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • The University of Kansas (KU) (Site #216)
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536-0001
        • Rekruttering
        • Kentucky Neuroscience Institute (Site #213)
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215-5400
        • Rekruttering
        • Beth Israel Deaconess Medical Center (Site #211)
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Rekruttering
        • University of Michigan Health System (UMHS) (Site #202)
      • Farmington Hills, Michigan, Forente stater, 48334-2973
        • Rekruttering
        • Quest Research Institute - Alcanza - PPDS (Site #201)
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • Rekruttering
        • University of New Mexico Health Sciences Center (Site #225)
    • New York
      • New York, New York, Forente stater, 10029-6501
        • Rekruttering
        • Mount Sinai School of Medicine (Site #209)
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Joan and Sanford I. Weill Department of Medicine (Site #224)
    • North Carolina
      • Asheville, North Carolina, Forente stater, 28806
        • Rekruttering
        • Asheville Neurology Specialists, P.A. (Site #229)
      • Durham, North Carolina, Forente stater, 27705
        • Rekruttering
        • Duke Neurological Disorders Clinic (Site #210)
    • Ohio
      • Cleveland, Ohio, Forente stater, 44195-0001
        • Rekruttering
        • Cleveland Clinic (Site #223)
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • The Ohio State University Wexner Medical Center (site #207)
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
        • Rekruttering
        • Vanderbilt University Medical Center (Site #204)
    • Texas
      • Cypress, Texas, Forente stater, 77429
        • Rekruttering
        • Horizon Clinical Research: Gill Neuroscience - Houston (Site #232)
      • Round Rock, Texas, Forente stater, 78681-3578
        • Rekruttering
        • Central Texas Neurology Consultants (Site #203)
    • Washington
      • Kirkland, Washington, Forente stater, 98034-3013
        • Rekruttering
        • EvergreenHealth (Site #219)

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

Participants must meet all of the following criteria to take part in the study:

  1. Be a man or woman between 30 and 80 years of age at the time of screening.
  2. Have a diagnosis of Parkinson's disease, confirmed using standard medical criteria, including slowness of movement and symptoms that affect one side of the body more than the other.
  3. Have mild to moderate Parkinson's disease, defined as stage 3 or lower on the Hoehn and Yahr scale when medications are working ("ON" state).
  4. Experience an average of at least 3 hours of OFF time per day, based on home symptom diaries, with at least 2.5 hours of OFF time each day during the baseline period.
  5. Have a Montreal Cognitive Assessment (MoCA) score of 24 or higher at screening.
  6. Be able to walk independently, with or without the use of a walking aid.
  7. Be able to swallow oral medication.
  8. Have been on a stable Parkinson's medication regimen for at least 4 weeks before screening. Medications known as MAO-B inhibitors must have been stable for at least 12 weeks.
  9. Be taking levodopa at least four times daily (immediate- or controlled-release formulations) or three times daily (extended-release formulations such as Rytary or Crexont).

Key Exclusion Criteria:

Participants cannot take part in the study if any of the following apply:

  1. Have a form of parkinsonism that is not typical Parkinson's disease, such as secondary or atypical parkinsonism.
  2. Have previously received, or plan to receive during the study, advanced Parkinson's therapies such as continuous levodopa or dopamine delivery systems, or Parkinson's disease-related brain surgery.
  3. Have dyskinesias (involuntary movements) that are severe enough, in the study doctor's opinion, to interfere with participation.
  4. Have a history of only certain types of dyskinesias (such as OFF-state, diphasic, myoclonic, or dystonic dyskinesias) without typical peak-dose dyskinesias.
  5. Are currently taking medications that block dopamine, except for low-dose quetiapine (up to 50 mg per day) used for insomnia.
  6. Routinely use on-demand "rescue" Parkinson's medications more than three times per week.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Oral tablet

Eksperimentell: Low Dose

AP-472 100 mg per day

Oral tablet

Oral tablet

Eksperimentell: High Dose

AP-472 300 mg per day

Oral tablet

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Endring fra baseline i gjennomsnittlig daglig OFF-tid på motordagbøker for AP-472 sammenlignet med placebo (normalisert til 16 timers våken tid)
Tidsramme: Uke 12
Uke 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Endring fra utgangspunkt i ON-tid uten plagsom dyskinesi (normalisert til 16 timer)
Tidsramme: Uke 12
Uke 12
Change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 2 (Motor Experiences of Daily Living (M-EDL)) score
Tidsramme: Week 12

For MDS-UPDRS Part II (Motor Experiences of Daily Living, M-EDL) there are 13 items each scored from 0 to 4. The total score range is from 0-52. A higher score indicates worse motor impact on daily activities; lower scores are better.

Week 12
Change from baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) summary index
Tidsramme: Week 12

For the Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index the score is calculated by averaging the 8 domain scores and converting them to a 0-100 scale. A higher score indicates worse health-related quality of life; lower scores are better.

Week 12
Change from baseline in MDS-UPDRS Part III (Motor Examination) score in the best ON state
Tidsramme: Week 12

The MDS-UPDRS Part III includes 33 items, each scored from 0 to 4. The total score range is from 0-132. A higher score indicates worse motor impairment; lower scores are better.

Week 12
Change from baseline in Epworth Sleepiness Scale (ESS) total score
Tidsramme: Week 12

The ESS consists of 8 items, each scored from 0 to 3. The total score range is from 0-24. Higher scores indicate greater daytime sleepiness; lower scores are better.

Week 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. februar 2026

Primær fullføring (Antatt)

3. september 2027

Studiet fullført (Antatt)

3. januar 2028

Datoer for studieregistrering

Først innsendt

29. januar 2026

Først innsendt som oppfylte QC-kriteriene

19. februar 2026

Først lagt ut (Faktiske)

25. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere